The University of Massachusetts Chan Medical School and Wellinks have launched “Healthy at Home,” a program to investigate whether virtual care can prevent recurrent illness and reduce health-related costs for people with chronic obstructive pulmonary disease (COPD). The six-month program will test the feasibility of virtual preventive care…
Despite treatment, a large number of people with chronic obstructive pulmonary disease (COPD) in the U.S. continue to experience a high symptom burden and frequent exacerbations, or episodes of sudden disease worsening, a study reported. Findings highlight the need to better understand the real-world effectiveness of COPD management strategies…
Nighttime breathing symptoms related to chronic obstructive pulmonary disease (COPD) significantly impaired daily activities and health-related quality of life, a survey of patients and physicians revealed. Most of the surveyed patients (74%) reported having nocturnal symptoms, while physicians reported that they prescribed treatments based on 24-hour symptom relief for…
Nuance Pharma has been given the go-ahead to launch clinical trials in China to evaluate the investigational therapy ensifentrine as a maintenance treatment for chronic obstructive pulmonary disease (COPD). The company asked permission, in the form of an investigational new drug (IND) application, to conduct both Phase 1…
Most people with chronic obstructive pulmonary disease (COPD) who participated in a U.S. pilot program of NuvoAir’s virtual monitoring service reported a decrease in hospitalizations and a better quality of life, the company announced. NuvoAir’s COPD solution uses proprietary home monitoring devices, including a spirometer and an…
Ensifentrine, Verona Pharma’s experimental inhalation therapy, safely and effectively improves lung function and reduces the rate and risk of exacerbations, or episodes of disease worsening, in people with moderate to severe chronic obstructive pulmonary disease (COPD). That is according to top-line, six-month data from the Phase 3 ENHANCE-2…
An experimental anti-inflammatory medication called DMX-700, being developed by Dimerix for chronic obstructive pulmonary disease (COPD), was found to substantially reduce lung injury in a mouse model of the disease. “DMX-700 has demonstrated some very encouraging pre-clinical data,” Nina Webster, PhD, CEO and managing director of Dimerix,…
Levels of a protein called LOXL1 are elevated in the lungs of people who smoke cigarettes, as well as in those with chronic obstructive pulmonary disease (COPD), a recent study reported. According to researchers, these findings highlight the importance of LOXL1 and similar proteins in disease processes associated with…
Salmeterol, combined with the root extract derivative magnesium isoglycyrrhizinate (MgIG), eased the signs and symptoms of chronic obstructive pulmonary disease (COPD) in rats, a study demonstrated. Salmeterol-MgIG combination therapy was more effective than the approved salmeterol-fluticasone combination in improving lung function and reducing inflammation. The researchers suggested…
Levels of the protein fibrinogen in the blood can be used to assess inflammation and the risk of non-invasive ventilation failure during acute exacerbations in people with chronic obstructive pulmonary disease (COPD), according to a new study. Fibrinogen is an inflammation-associated protein that is known as a biomarker for…
Get regular updates to your inbox.